坎地沙坦联合苯磺酸左旋氨氯地平治疗早期糖尿病肾病合并高血压疗效分析  

Efficacy analysis of candesartan combined with levoamlodipine besylate in the treatment of early diabetic nephropathy with hypertension

作　　者：罗锡坤 李玉梅 谢宗明 LUO Xi-kun;LI Yu-mei;XIE Zong-ming(Yangchun People’s Hospital,Department of Internal Medicine-Cardiovascular,Yangjiang 529600,China)

机构地区：[1]广东省阳江市阳春市人民医院心血管内科二区

出　　处：《中国现代药物应用》2019年第23期104-105,共2页Chinese Journal of Modern Drug Application

摘　　要：目的探讨坎地沙坦联合苯磺酸左旋氨氯地平治疗早期糖尿病肾病(DN)合并高血压的临床效果。方法 200例早期糖尿病肾病合并高血压患者,按照药物治疗方案的不同分为坎地沙坦组(65例,给予坎地沙坦治疗)、苯磺酸左旋氨氯地平组(70例,给予苯磺酸左旋氨氯地平治疗)和联合用药组(65例,给予坎地沙坦联合苯磺酸左旋氨氯地平治疗)。比较三组患者治疗前后的血压和24 h尿蛋白水平。结果治疗后,三组患者的舒张压、收缩压及24 h尿蛋白水平均较本组治疗前降低,差异均具有统计学意义(P<0.05)。联合用药组患者的舒张压、收缩压、24 h尿蛋白水平分别为(125.45±10.50)mm Hg(1 mm Hg=0.133 kPa)、(78.50±7.50)mm Hg、(87.45±20.50)mg/24 h,均低于坎地沙坦组的(138.55±13.25)mm Hg、(84.75±8.50)mm Hg、(132.50±20.05)mg/24 h和苯磺酸左旋氨氯地平组的(136.45±13.00)mm Hg、(83.95±8.00)mm Hg、(129.15±20.50)mg/24 h,差异均具有统计学意义(P<0.05)。坎地沙坦组和苯磺酸左旋氨氯地平组的舒张压、收缩压及24 h尿蛋白水平比较,差异均无统计学意义(P>0.05)。结论对早期糖尿病肾病合并高血压患者给予坎地沙坦联合苯磺酸左旋氨氯地平治疗,能提升患者的疗效,稳定患者血尿水平,具有积极的推广价值。Objective To discuss the clinical effect of candesartan combined with levoamlodipine besylate in the treatment of early diabetic nephropathy with hypertension. Methods A total of 200 patients with early diabetic nephropathy with hypertension were divided into candesartan group(65 cases, treated with candesartan), levoamlodipine besylate group(70 cases, treated with levoamlodipine besylate) and combination group(65 cases, treated with candesartan combined with levoamlodipine besylate) by different treatment regimens. The blood pressure and 24 h urinary protein level before and after treatment was compared in the three groups. Results After treatment, the levels of diastolic blood pressure, systolic blood pressure and 24 h urinary protein in three groups was lower than those before treatment, and their difference was statistically significant(P<0.05). The levels of diastolic blood pressure, systolic blood pressure and 24 h urinary protein were(125.45±10.50) mm Hg(1 mm Hg=0.133 kPa),(78.50±7.50) mm Hg and(87.45±20.50) mg/24 h respectively in combination group, which was lower than(138.55±13.25) mm Hg,(84.75±8.50) mm Hg and(132.50±20.05) mg/24 h in candesartan group, and(136.45±13.00) mm Hg,(83.95±8.00) mm Hg and(129.15±20.50) mg/24 h in levoamlodipine besylate group. Their difference was statistically significant(P<0.05). There was no statistically significant difference in levels of diastolic blood pressure, systolic blood pressure and 24 h urinary protein between candesartan group and levoamlodipine besylate group(P>0.05). Conclusion For early diabetic nephropathy patients with hypertension, candesartan combined with levoamlodipine besylate can improve the efficacy, stabilize the blood urine level, and it contains positive promotion value.

关 键 词：早期糖尿病肾病 高血压 坎地沙坦 苯磺酸左旋氨氯地平 

分 类 号：R54[医药卫生—心血管疾病]